Introduction
============

Lung cancer is a leading cause of cancer mortality in the USA and other developed countries.[@b1-dddt-9-2171] The two major forms of the disease are non-small cell lung cancer and small cell lung cancer, which account for 85% and 15% of all lung cancers, respectively.[@b2-dddt-9-2171] Despite advances in preliminary detection and standard treatment with combination chemotherapy and radiotherapy, the prognosis for patients with lung cancer has not improved significantly in the last 20 years,[@b3-dddt-9-2171],[@b4-dddt-9-2171] and survival rates have changed little over the past 2 decades. Currently, an enormous amount of research is aimed at understanding the molecular and cellular biology of lung cancer; however, much more work is needed to better understand the correlation between gene regulation and lung cancer.

DNA methylation is an important epigenetic mechanism for gene silencing. Growing evidence shows that aberrant hypermethylation in 5′-CpG islands in the promoter regions is a major mechanism for silencing tumor suppressor or other cancer-associated genes in many kinds of human cancer.[@b5-dddt-9-2171]--[@b8-dddt-9-2171] Loss of function in cancer suppressor genes may hinder inhibition of growth of cancer cells, which leads to malignant transcription and translation during replication of DNA. A number of genes, including the cyclin-dependent kinase inhibitor (p16), the tumor suppressor gene Ras association domain family protein 1A, Kelch-like ECH-associating protein 1, the DNA repair gene *MGMT*, and the cystic fibrosis transmembrane conductance regulator are demonstratively methylated in lung cancer.[@b9-dddt-9-2171]--[@b12-dddt-9-2171] CDH1, a member of the transmembrane glycoprotein family, also known as cadherin-1, CAM 120/80, epithelial cadherin (E-cadherin), or uvomorulin, is encoded by the *CDH1* gene (16q22.1).[@b13-dddt-9-2171] CDH1 is a calcium-dependent cell-cell adhesion glycoprotein containing three domains, ie, five extracellular cadherin repeats, a transmembrane region, and a highly conserved cytoplasmic tail.[@b14-dddt-9-2171] *CDH1* as a tumor suppressor gene plays an essential role in maintaining cell adhesion and adherent junctions in normal tissues. *CDH1* expression is frequently absent in a variety of epithelial tumors, and loss of normal intercellular junctions results in promotion of cancer invasion and metastasis and is correlated with several types of cancers.[@b15-dddt-9-2171]--[@b17-dddt-9-2171] However, the association between and clinicopathological significance of CDH1 promoter hypermethylation and lung cancer remains unclear. In this study, we systematically investigate studies of *CDH1* promoter hypermethylation and lung cancer, and validate the association between *CDH1* promoter hypermethylation and lung cancer using meta-analysis methods. In addition, we summarize these findings and discuss tumor suppressor function, as well as the clinicopathological significance of *CDH1* in lung cancer.

Materials and methods
=====================

Publication selection
---------------------

A systematic literature searching was performed using PubMed, Embase, and the Web of Science up to August 13, 2014 without any language restrictions. The following keywords and terms were used: \[methylation or DNA methylation or hypermethylation or de-methylation\] and \[CDH1 or cadherin-1 or CAM 120/80 or epithelial cadherin (E-cadherin) or uvomorulin\] and \[lung cancer or lung carcinoma or lung tumor\]. References from these publications were manually searched to identify additional studies. The published scientific articles were restricted to English language, and conference abstracts were excluded due to lack of sufficient data. Titles, abstracts, and key words in the articles were initially evaluated for inclusion criteria. Details and additional information were identified and collected from the full text of these articles.

Inclusion and exclusion criteria
--------------------------------

A study included for meta-analysis needed to have: evaluated the correlation between *CDH1* methylation and lung cancer; included a clinical cohort and controls; included at least three patients and controls; used methylation-specific polymerase chain reaction or quantitative methylation-specific polymerase chain reaction to examine *CDH1* methylation and expression; and used tissue data rather than blood data. Studies that did not meet our inclusion criteria were excluded. When the same groups of patients were reported in multiple papers, only the most recent and complete paper was selected to avoid overlap.

Data extraction and quality assessment
--------------------------------------

Two researchers independently collected the information and extracted the data regarding authorship, year, source of publication, inclusion criteria, *CDH1* methylation frequency, sex status, smoking history, pathological type, clinical staging, degree of differentiation, lymph node metastasis, epidermal growth factor receptor status, and prognosis in patients and controls. Any discrepancy was resolved by discussion until agreement was reached. The data are summarized in [Table 1](#t1-dddt-9-2171){ref-type="table"} according to the criteria mentioned above. Methodological evaluation was assessed by the researchers according to the REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guidelines and ELCWP (European Lung Cancer Working Party) score.[@b18-dddt-9-2171],[@b19-dddt-9-2171]

Data analysis
-------------

The meta-analysis was performed using Reviewer Manager 5 (Cochrane Collaboration, Oxford, UK). Pooled odds ratios (ORs) and confidence intervals (CIs) were calculated to assess the correlation between *CDH1* methylation and lung cancer. Cochran's *Q* test and *I* [@b2-dddt-9-2171] were used to assess heterogeneity among the studies.[@b20-dddt-9-2171] A *Q* test showing *P*\<0.05 or an *I* [@b2-dddt-9-2171] test \>50% indicated significant heterogeneity and a fixed-effects model was used to calculate the parameters. Otherwise, a random-effects model was used to pool data and attempt to identify potential sources of heterogeneity based on subgroup analyses.[@b21-dddt-9-2171],[@b22-dddt-9-2171] Publication bias was assessed by Begg's test and use of funnel plots.[@b23-dddt-9-2171] The analysis of meta-regression and publication bias was performed using Stata version 10.0 (Statacorp, College Station, TX, USA).

Results
=======

The process followed to select the papers used in this report is shown in [Figure 1](#f1-dddt-9-2171){ref-type="fig"}. Ninety papers were identified by electronic database searching and 20 further papers by manual searching. Eighty-five papers were excluded for being duplicate publications, being an irrelevant title or abstract, or being a relevant title and abstract but not published in the English language. After retrieval of the full-text articles, eleven papers were excluded for not having a large enough study population or for being reviews. Thirteen further studies were screened out (involving 866 cases and 757 controls) based on the inclusion and exclusion criteria in the pooled analysis. The characteristics of the studies are shown in [Table 1](#t1-dddt-9-2171){ref-type="table"}.[@b24-dddt-9-2171]--[@b36-dddt-9-2171] Six papers were used to study the correlation between *CDH1* methylation and sex status. Five papers provided smoking history data, allowing an investigation of the influence of smoking on *CDH1* methylation. Six studies included pathological typing (squamous small carcinoma or adenocarcinoma). Three studies investigated the effect of clinical stage, ie, stage I, II, III, or IV. One paper discussed lymph node metastasis and another discussed degree of differentiation.

Analyzing tissue samples from 657 patients and 593 controls, the mean frequency of *CDH1* methylation was 32% (range 8.33% to 66.32%) in tumor tissue and 9% (range 0.00%--27.78%) in tissue from controls. This result indicates that the occurrence of *CDH1* methylation is higher in tumor tissue than in normal tissue. Using the fixed model, meta-analysis showed that 657 cases and 593 controls from 12 studies were pooled OR as shown in [Figure 2](#f2-dddt-9-2171){ref-type="fig"} (OR 3.89, 95% CI 2.87--5.27, *P*\<0.00001). These findings indicate that *CDH1* methylation is a key molecular event in tumor tissue but not in normal tissue.

The results also show heterogeneity across the included studies (*I* [@b2-dddt-9-2171] is 61%, ie, more than 50%). Given this significant heterogeneity, a subgroup analysis was performed to investigate sex status, smoking history, pathological type, clinical stage, differentiation degree, and lymph node metastasis to observe the relationship between *CDH1* methylation and clinical characteristics (see [Figure 3](#f3-dddt-9-2171){ref-type="fig"}). However, there was no correlation between *CDH1* promoter methylation and any of these factors (sex status, OR 0.78, 95% CI 0.41--1.50, *P*=0.46; smoking history, OR 0.97, 95% CI 0.53--1.79, *P*=0.93; pathological type, OR 0.97, 95% CI 0.59--1.60, *P*=0.91; clinical stage, OR 1.48, 95% CI 0.81--2.68, *P*=0.2; lymph node metastasis, OR 0.68, 95% CI 0.13--3.63, *P*=0.65; and differentiation degree, OR 1.01, 95% CI 0.34--3.02, *P*=0.99).

The stability of the results was tested by sensitivity analysis. The OR ranged from 0.78 to 3.89, which was not a significant change, suggesting that the results of our meta-analysis were not significantly unstable. The funnel plot shown in [Figure 4](#f4-dddt-9-2171){ref-type="fig"} is partially symmetric, indicating low publication bias regarding *CDH1* methylation in lung cancer.

Discussion
==========

DNA methylation is an important epigenetic mechanism for regulation of gene expression. An imbalance of gene methylation can cause a variety of human diseases. Hypermethylation of tumor suppressor genes and hypomethylation of oncogenes are two essential components of the molecular mechanism involved in the epigenomic regulation of initiation and progression of cancer. As a tumor suppressor gene, *CDH1* maintains cell-cell adhesion and keeps epithelial cells arranged in normal arrangement and layer. In vitro studies demonstrate that loss of expression or function of *CDH1* can activate transcription factors associated with epithelial-mesenchymal transition, leading to metastasis of cancer cells.[@b37-dddt-9-2171] *CDH1* methylation has been detected in several types of carcinoma, including breast cancer, gastric cancer, and lung cancer.[@b38-dddt-9-2171]--[@b40-dddt-9-2171] A comprehensive evaluation of markers of methylation in lung cancer is needed to better understand the relationship between *CDH1* methylation and lung cancer. Although a large number of studies have demonstrated a possible relationship between *CDH1* methylation and lung cancer, a meta-analysis can summarize the relevant studies and compare different subgroup characteristics.

In this meta-analysis, we mainly focus on the correlation between *CDH1* methylation and lung cancer. We analyzed data from 13 studies that included 657 tumor tissue samples and 593 control samples. The results show that the *CDH1* methylation level in the cancer group was significantly higher than in the control group. The pooled OR using the fixed-effect model was 3.89 (95% CI 2.87--5.27 versus the control group). *CDH1* methylation plays a key role in the induction of lung cancer due to silencing of the tumor suppressor gene *CDH1*. This conclusion is consistent with that of a previous study.[@b36-dddt-9-2171] Since changes in *CDH1* promoter hypermethylation are reversible, drug treatment promoting demethylation may be useful for delaying carcinogenesis and progression. Treatment with 5-aza-2′-deoxycytidine showed that migration of A549 cells decreased markedly upon restoration of CDH1.[@b41-dddt-9-2171] These preclinical studies show the therapeutic potential of restoration of tumor suppressor expression via epigenetic modulation. This approach may bring hope for patients with cancer through gene-targeted therapy.

We further determined the clinicopathological significance of *CDH1* promoter hypermethylation in patients with lung cancer. For smoking history, the summary OR was 0.97 (95% CI 0.53--1.79) in the 65 cases and 27 controls. The results show that methylation level of *CDH1* is not associated with smoking history. Lung cancer is a complicated disease with different genetic and epigenetic profiling. Smoking is not the only risk factor for lung cancer. Smoking may target other specific genes for methylation or mutation, for example, methylenetetrahydrofolate reductase.[@b33-dddt-9-2171] Other subgroup meta-analysis was performed, including for sex status (OR 0.78, 95% CI 0.41--1.50), pathological type (OR 0.97, 95% CI 0.59--1.60), clinical stage (OR 1.48, 95% CI 0.81--2.68), lymph node metastasis (OR 0.68, 95% CI 0.13--3.63), and degree of differentiation (OR 1.01, 95% CI 0.34--3.02). *CDH1* methylation determined by clinical staging shows a slightly more significant association than the other subgroups. Interestingly, *CDH1* methylation was detected much more frequently in stages III and IV than in stages I and II. However, *CDH1* methylation itself does not correlate with pathological type, sex status, lymph node metastasis, or degree of differentiation. Possible reasons for this finding might be the widely heterogeneous results for the subgroups or the lack of cases and controls in the subgroups. Other potentially significant factors may need to be investigated, such as patient age, tumor size, and biopsy sample control.[@b42-dddt-9-2171]

Conclusion
==========

*CDH1* promoter methylation is associated with lung cancer based on this meta-analysis. *CDH1* methylation might be a biomarker of lung cancer, with potential value in predicting the prognosis of the disease, and warrants further studies involving more clinical cases for meta-analysis in the future. In addition, the potential variables on *CDH1* methylation from different group database are still not clear due to the limitation of the statistical power of meta-analysis.
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![Flow diagram of the literature search strategy and assessment of studies identified for meta-analysis.\
**Abbreviation:** EMBASE, Excerpta Medica dataBASE.](dddt-9-2171Fig1){#f1-dddt-9-2171}

![Estimates for *CDH1* methylation frequency associated with lung cancer in the meta-analysis.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel; OR, odds ratio.](dddt-9-2171Fig2){#f2-dddt-9-2171}

###### 

Clinicopathological significance of *CDH1* hypermethylation rate in patients with lung cancer. Forest plots for the relationship between *CDH1* methylation frequency and lung cancer. (**A**) Sex status, (**B**) smoking history, (**C**) pathological type, (**D**) clinical staging, (**E**) degree of differentiation, and (**F**) lymph node metastasis.

**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel; OR, odds ratio.
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![Funnel plot analysis of *CDH1* hypermethylation rate in patients with lung cancer. Funnel plot for assessment of publication bias in the meta-analysis. (**A**) Cases versus control, (**B**) sex status, (**C**) smoking history, (**D**) pathological type, (**E**) clinical staging, (**F**) degree of differentiation, and (**G**) lymph node metastasis, respectively.\
**Abbreviations:** OR, odds ratio; SE, standard error of the mean.](dddt-9-2171Fig4){#f4-dddt-9-2171}

###### 

Characteristics of the included studies

  Authors                                    Years   Samples   Sex status   Smoking history   Pathological types   Clinical staging                             
  ------------------------------------------ ------- --------- ------------ ----------------- -------------------- ------------------ ---- ----- ---- ---- ---- ----
  Zochbauer-Muller et al[@b24-dddt-9-2171]   2001    107       104          76                31                   98                 9    43    45   61   21   25
  Yanagawa et al[@b25-dddt-9-2171]           2003    75        75           54                21                   20                 55   29    43   24   33   42
  Russo et al[@b26-dddt-9-2171]              2005    49        49           --                --                   22                 5    --    --   --   --   --
  Tsou et al[@b27-dddt-9-2171]               2005    7         11           --                --                   --                 --   --    --   --   --   --
  Kim et al[@b28-dddt-9-2171]                2007    88        88           70                18                   72                 16   53    35   51   37   
  Tan et al[@b29-dddt-9-2171]                2007    20        10           --                --                   --                 --   --    --   --   --   --
  Feng et al[@b30-dddt-9-2171]               2007    49        49           26                23                   --                 --   14    20   21   17   --
  Wang et al[@b31-dddt-9-2171]               2007    28        12           17                11                   --                 --   7     15   --   --   --
  Wang et al[@b32-dddt-9-2171]               2008    95        95           19                76                   --                 --   35    45   31   26   34
  Vaissiere et al[@b33-dddt-9-2171]          2009    209       164          171               38                   173                36   121   58   --   --   --
  Begum et al[@b34-dddt-9-2171]              2011    76        30           40                36                   --                 --   26    36   41   17   11
  Guzman et al[@b35-dddt-9-2171]             2012    26        33           26                33                   --                 --   25    7    --   --   --
  Zheng et al[@b36-dddt-9-2171]              2012    37        37           26                11                   --                 --   15    17   --   --   --

**Note:** "--" means data not available.
